Seelos Aims For Conservative Approach After ALS Drug Shows Efficacy Signal
Executive Summary
CEO Raj Mehta told Scrip Seelos anticipates conducting a Phase III study of SLS-005 after the cohort in HEALEY ALS failed overall, but indicated some efficacy in patients not receiving Relyvrio.